High neutrophil-to-lymphocyte ratio before starting anti-programmed cell death 1 immunotherapy predicts poor outcome in patients with metastatic melanoma
Garnier, M.; Zaragoza, J.; Bénéton, N.; Bens, G.; Meurisse, V.; Samimi, M.; Maillard, Hé.; Machet, L.
Journal of the American Academy of Dermatology 79(1): 165-167.E2
2018
ISSN/ISBN: 0190-9622 PMID: 29544740 DOI: 10.1016/j.jaad.2018.03.006
Accession: 065194693
PDF emailed within 0-6 h: $19.90
Related References
Teterycz, P.ł; Jagodzińska-Mucha, P.; Cybulska-Stopa, B.że.; Mariuk-Jarema, A.; Kozak, K.; Koseła-Paterczyk, H.; Czarnecka, A.M.; Rajczykowski, M.; Dziura, R.; Galus, Łu.; Mackiewicz, J.; Świtaj, T.; Klimczak, A.; Falkowski, S.; Suwiński, R.ł; Ziobro, M.; Ługowska, I.; Rutkowski, P. 2018: High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors Melanoma Research 28(5): 435-441Minowa, T.; Kato, J.; Hida, T.; Horimoto, K.; Sato, S.; Sawada, M.; Uhara, H. 2018: Prognostic role of neutrophil to lymphocyte ratio in advanced melanoma treated with anti-programmed death-1 therapy Journal of Dermatology 45(9): E250-E251
Rossi, L.; Santoni, M.; Crabb, S.J.; Scarpi, E.; Burattini, L.; Chau, C.; Bianchi, E.; Savini, A.; Burgio, S.L.; Conti, A.; Conteduca, V.; Cascinu, S.; De Giorgi, U. 2015: High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer Annals of Surgical Oncology 22(4): 1377-1384
Finon, A.; Zaragoza, J.; Maillard, H.é; Beneton, N.; Bens, G.; Samimi, M.; Caille, A.ès.; Machet, L. 2018: A high neutrophil to lymphocyte ratio prior to BRAF inhibitor treatment is a predictor of poor progression-free survival in patients with metastatic melanoma European Journal of Dermatology: Ejd 28(1): 38-43
Yao, A.; Sejima, T.; Iwamoto, H.; Masago, T.; Morizane, S.; Honda, M.; Takenaka, A. 2015: High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy International Journal of Urology: Official Journal of the Japanese Urological Association 22(9): 827-833
Aktepe, O.H.; Güner, G.ür.; Güven, D.C.; Şahin, T.K.; Ardıç, F.S.; Yüce, D.; Yalçın, Şu.; Erman, M. 2021: The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma Turkish Journal of Medical Sciences 51(2): 757-765
Lin, G.-N.; Peng, J.-W.; Liu, P.-P.; Liu, D.-Y.; Xiao, J.-J.; Chen, X.-Q. 2017: Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment Asia-Pacific Journal of Clinical Oncology 13(5): E189-E194
Shao, N.; Cai, Q. 2015: High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer Clinical and Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 17(10): 772-778
Sadeghi, F.; Sarkady, F.; Zsóri, K.S.; Szegedi, I.án.; Orbán-Kálmándi, R.; Székely, E.G.; Vasas, N.; Berényi, E.; Csiba, L.ás.ó; Bagoly, Z.; Shemirani, A.H. 2022: High Neutrophil-Lymphocyte Ratio and Low Lymphocyte-Monocyte Ratio Combination after Thrombolysis Is a Potential Predictor of Poor Functional Outcome of Acute Ischemic Stroke Journal of Personalized Medicine 12(8)
Vajavaara, H.; Leivonen, S.-K.; Jørgensen, J.; Holte, H.; Leppä, S. 2022: Low lymphocyte-to-monocyte ratio predicts poor outcome in high-risk aggressive large B-cell lymphoma Ejhaem 3(3): 681-687
Chandrasekara, S.; Davis, S.; Thomson, P.; Haydon, A. 2018: High neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy Asia-Pacific Journal of Clinical Oncology 14(5): E442-E447
Szkandera, J.; Gerger, A.; Liegl-Atzwanger, B.; Stotz, M.; Samonigg, H.; Friesenbichler, J.; Stojakovic, T.; Leithner, A.; Pichler, M. 2015: The derived neutrophil/lymphocyte ratio predicts poor clinical outcome in soft tissue sarcoma patients American Journal of Surgery 210(1): 111-116
Qiu, X.; Song, Y.; Cui, Y.; Liu, Y. 2018: Increased neutrophil-lymphocyte ratio independently predicts poor survival in non-metastatic triple-negative breast cancer patients Iubmb Life 70(6): 529-535
Han, S.; Liu, Y.; Li, Q.; Li, Z.; Hou, H.; Wu, A. 2015: Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma Bmc Cancer 15: 617
Sangkhamanon, S.; Jongpairat, P.; Sookprasert, A.; Wirasorn, K.; Titapun, A.; Pugkhem, A.; Ungareevittaya, P.; Chindaprasirt, J. 2017: Programmed Death-Ligand 1 (PD-L1) Expression Associated with a High Neutrophil/Lymphocyte Ratio in Cholangiocarcinoma Asian Pacific Journal of Cancer Prevention: Apjcp 18(6): 1671-1674
Ferrucci, P.F.; Gandini, S.; Battaglia, A.; Alfieri, S.; Di Giacomo, A.M.; Giannarelli, D.; Cappellini, G.C.Antonini.; De Galitiis, F.; Marchetti, P.; Amato, G.; Lazzeri, A.; Pala, L.; Cocorocchio, E.; Martinoli, C. 2015: Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients British Journal of Cancer 112(12): 1904-1910
Tsukioka, T.; Izumi, N.; Komatsu, H.; Inoue, H.; Ito, R.; Suzuki, S.; Nishiyama, N. 2022: Large Tumor Size and High Neutrophil-to-lymphocyte Ratio Predicts Poor Prognosis After Pneumonectomy or Sleeve Lobectomy in Patients with Non-small-cell Lung Cancer Anticancer Research 42(6): 3029-3034
Krenn-Pilko, S.; Langsenlehner, U.; Stojakovic, T.; Pichler, M.; Gerger, A.; Kapp, K.S.; Langsenlehner, T. 2016: The elevated preoperative derived neutrophil-to-lymphocyte ratio predicts poor clinical outcome in breast cancer patients Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine 37(1): 361-368
Hwang, S.Ji.Eun.; Park, J.Jae.Won.; Wakade, D.; Chou, S.; Byth, K.; Fernandez-Penas, P. 2019: Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma Melanoma Research 29(2): 172-177
Ha, H.; Nam, A-Rong.; Bang, J-Hee.; Park, J-Eun.; Kim, T-Yong.; Lee, K-Hun.; Han, S-Won.; Im, S-Ah.; Kim, T-You.; Bang, Y-Jue.; Oh, D-Youn. 2016: Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy Oncotarget 7(47): 76604-76612